<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33486852</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1549-490X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>26</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>The oncologist</Title>
          <ISOAbbreviation>Oncologist</ISOAbbreviation>
        </Journal>
        <ArticleTitle>EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia.</ArticleTitle>
        <Pagination>
          <StartPage>242</StartPage>
          <EndPage>249</EndPage>
          <MedlinePgn>242-249</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/onco.13685</ELocationID>
        <Abstract>
          <AbstractText>On November 5, 2020, a marketing authorization valid through the European Union (EU) was issued for acalabrutinib monotherapy or acalabrutinib in combination with obinutuzumab (AcalaObi) in adult patients with treatment-naïve (TN) chronic lymphocytic leukemia (CLL) and also for acalabrutinib monotherapy in adult patients with relapsed or refractory (RR) CLL. Acalabrutinib inhibits the Bruton tyrosine kinase, which plays a significant role in the proliferation and survival of the disease. Acalabrutinib was evaluated in two phase III multicenter randomized trials. The first trial (ACE-CL-007) randomly allocated acalabrutinib versus AcalaObi versus chlorambucil plus obinutuzumab (ChlObi) to elderly/unfit patients with TN CLL. The progression-free survival (PFS), as assessed by an independent review committee, was superior for both the AcalaObi (hazard ratio [HR], 0.1; 95% confidence interval [CI], 0.06-0.17) and acalabrutinib (HR, 0.2; 95% CI, 0.13-0.3) arms compared with the ChlObi arm. The second trial (ACE-CL-309) randomly allocated acalabrutinib versus rituximab plus idelalisib or bendamustine to adult patients with RR CLL. Also in this trial, the PFS was significantly longer in the acalabrutinib arm (HR, 0.31; 95% CI, 0.20-0.49). Adverse events for patients receiving acalabrutinib varied across trials, but the most frequent were generally headache, diarrhea, neutropenia, nausea, and infections. The scientific review concluded that the benefit-risk ratio of acalabrutinib was positive for both indications. This article summarizes the scientific review of the application leading to regulatory approval in the EU. IMPLICATIONS FOR PRACTICE: Acalabrutinib was approved in the European Union for the treatment of adult patients with chronic lymphocytic leukemia who have not received treatment before and for those who have received therapy but whose disease did not respond or relapsed afterward. Acalabrutinib resulted in a clinically meaningful and significant lengthening of the time from treatment initiation to further disease relapse or patient's death compared with standard therapy. The overall safety profile was considered acceptable, and the benefit-risk ratio was determined to be positive.</AbstractText>
          <CopyrightInformation>© 2021 AlphaMed Press.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Delgado</LastName>
            <ForeName>Julio</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-5157-4376</Identifier>
            <AffiliationInfo>
              <Affiliation>Oncology and Hematology Office, European Medicines Agency, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Hematology, Hospital Clinic, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Josephson</LastName>
            <ForeName>Filip</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Lakemedelsverket, Uppsala, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Camarero</LastName>
            <ForeName>Jorge</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Agencia Espanola de los Medicamentos y Productos Sanitarios, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garcia-Ochoa</LastName>
            <ForeName>Blanca</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Agencia Espanola de los Medicamentos y Productos Sanitarios, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lopez-Anglada</LastName>
            <ForeName>Lucia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Agencia Espanola de los Medicamentos y Productos Sanitarios, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Prieto-Fernandez</LastName>
            <ForeName>Carolina</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Agencia Espanola de los Medicamentos y Productos Sanitarios, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Hennik</LastName>
            <ForeName>Paula B</ForeName>
            <Initials>PB</Initials>
            <AffiliationInfo>
              <Affiliation>Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medicines Evaluation Board, Utrecht, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Papadouli</LastName>
            <ForeName>Irene</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology and Hematology Office, European Medicines Agency, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gisselbrecht</LastName>
            <ForeName>Christian</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Hopital Saint Louis, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Enzmann</LastName>
            <ForeName>Harald</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pignatti</LastName>
            <ForeName>Francesco</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Oncology and Hematology Office, European Medicines Agency, Amsterdam, The Netherlands.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>02</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Oncologist</MedlineTA>
        <NlmUniqueID>9607837</NlmUniqueID>
        <ISSNLinking>1083-7159</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4F4X42SYQ6</RegistryNumber>
          <NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I42748ELQW</RegistryNumber>
          <NameOfSubstance UI="C000604908">acalabrutinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015451" MajorTopicYN="Y">Leukemia, Lymphocytic, Chronic, B-Cell</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Acalabrutinib</Keyword>
        <Keyword MajorTopicYN="Y">Bruton tyrosine kinase</Keyword>
        <Keyword MajorTopicYN="Y">Chronic lymphocytic leukemia</Keyword>
        <Keyword MajorTopicYN="Y">European Medicines Agency</Keyword>
      </KeywordList>
      <CoiStatement>
<i>Disclosures of potential conflicts of interest may be found at the end of this article</i>.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>20</Hour>
          <Minute>54</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33486852</ArticleId>
        <ArticleId IdType="pmc">PMC7930415</ArticleId>
        <ArticleId IdType="doi">10.1002/onco.13685</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Swerdlow SH, Campo E, Pileri SA et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood
2016;127:2375–2390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4874220</ArticleId>
            <ArticleId IdType="pubmed">26980727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sant M, Allemani C, Tereanu C et al. Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project. Blood
2010;116:3724–3734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20664057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hallek M.
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol
2019;94:1266–1287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31364186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hallek M, Cheson BD, Catovsky D et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood
2018;131:2745–2760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29540348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet
2007;370:230–239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17658394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Flinn IW, Neuberg DS, Grever MR et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol
2007;25:793–798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17283364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first‐line therapy of younger patients with chronic lymphocytic leukemia. Blood
2006;107:885–891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16219797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Keating MJ, O'Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol
2005;23:4079–4088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15767648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wierda W, O'Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol
2005;23:4070–4078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15767647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hallek M, Fischer K, Fingerle‐Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open‐label, phase 3 trial. Lancet
2010;376:1164–1174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20888994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Robak T, Dmoszynska A, Solal‐Celigny P et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression‐free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol
2010;28:1756–1765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20194844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Goede V, Fischer K, Busch R et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med
2014;370:1101–1110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24401022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Eichhorst B, Fink AM, Bahlo J et al. First‐line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open‐label, randomised, phase 3, non‐inferiority trial. Lancet Oncol
2016;17:928–942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27216274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Byrd JC, Brown JR, O'Brien S et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med
2014;371:213–223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4134521</ArticleId>
            <ArticleId IdType="pubmed">24881631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Roberts AW, Davids MS, Pagel JM et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med
2016;374:311–322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7107002</ArticleId>
            <ArticleId IdType="pubmed">26639348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Furman RR, Sharman JP, Coutre SE et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med
2014;370:997–1007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4161365</ArticleId>
            <ArticleId IdType="pubmed">24450857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wiestner A. Emerging role of kinase‐targeted strategies in chronic lymphocytic leukemia. Blood
2012;120:4684–4691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3520616</ArticleId>
            <ArticleId IdType="pubmed">22875912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Barf T, Covey T, Izumi R et al. Acalabrutinib (ACP‐196): A covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharmacol Exp Ther
2017;363:240–252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28882879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Byrd JC, Harrington B, O'Brien S et al. Acalabrutinib (ACP‐196) in relapsed chronic lymphocytic leukemia. N Engl J Med
2016;374:323–332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4862586</ArticleId>
            <ArticleId IdType="pubmed">26641137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Byrd JC, Wierda WG, Schuh A et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: Updated phase 2 results. Blood
2020;135:1204–1213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7146022</ArticleId>
            <ArticleId IdType="pubmed">31876911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sharman JP, Egyed M, Jurczak W et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment‐naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial. Lancet
2020;395:1278–1291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32305093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ghia P, Pluta A, Wach M et al. ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol
2020;38:2849–2861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32459600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Woyach JA, Blachly JS, Rogers KA et al. Acalabrutinib plus obinutuzumab in treatment‐naive and relapsed/refractory chronic lymphocytic leukemia. Cancer Discov
2020;10:394–405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31915195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sun C, Nierman P, Kendall EK et al. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. Blood
2020;136:93–105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7332900</ArticleId>
            <ArticleId IdType="pubmed">32202637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Owen RG, McCarthy H, Rule S et al. Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: A single‐arm, multicentre, phase 2 study. Lancet Haematol
2020;7:e112–e121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31866281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang M, Rule S, Zinzani PL et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE‐LY‐004): A single‐arm, multicentre, phase 2 trial. Lancet
2018;391:659–667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7864374</ArticleId>
            <ArticleId IdType="pubmed">29241979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Burger JA, Tedeschi A, Barr PM et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med
2015;373:2425–2437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4722809</ArticleId>
            <ArticleId IdType="pubmed">26639149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moreno C, Greil R, Demirkan F et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first‐line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open‐label, phase 3 trial. Lancet Oncol
2019;20:43–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30522969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Eichhorst B, Robak T, Montserrat E et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol
2015;26(suppl 5):v78–v84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26314781</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
